CorWave
CorWave develops blood pumps based on a unique and patented wave membrane pumping technology. The membrane is the result of more than twenty years of research and development, and is capable of mimicking the native heart. This disruptive technology radically differentiates CorWave products from commercially-available rotary pump LVADs.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.corwave.com
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Related News
CorWave announces successful completion of 6-month chronic in vivo study, paving the way for clinical trial initiation
CorWave announces the appointment of Dawn Sadlowski-Buisserez as Vice President of Operations to support the ramp-up of production
CorWave announces the appointment of Fairuz Hasni as Vice President Human Resources
CorWave announces the Grand opening of its manufacturing facility on the banks of the Seine, next to Paris
CorWave announces the appointment of Magalie Durrèche as Chief Financial Officer
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.